NCT01907815: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia |
|
|
| Terminated | 2 | 24 | US | Akt Inhibitor GSK2141795, GSK2141795, Oral Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist | National Cancer Institute (NCI) | Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia | 01/16 | 01/16 | | |
